

Daftar Pustaka

1. Statement on the Fifteenth Meeting of the IHR (2005) Emergency Committee on the COVID-19 Pandemic. Who.int. 2023. <https://www.who.int/news/item/05-05-2023-statement-on-the-fifteenth-meeting-of-the-international-health-regulations-%282005%29-emergency-committee-regarding-the-coronavirus-disease-%28covid-19%29-pandemic>
2. WHO. COVID-19 epidemiological update – 22 December 2023. *World Health Organ.* 2023;(December 2023):26.
3. Healey Q, Sheikh A, Daines L, Vasileiou E. Symptoms and signs of long COVID: A rapid review and meta-analysis. *J Glob Health.* 2022;12:05014. doi:10.7189/jogh.12.05014
4. Lau EH, Hui DS, Tsang OT, et al. Long-term persistence of SARS-CoV-2 neutralizing antibody responses after infection and estimates of the duration of protection. *eClinicalMedicine.* 2021;41:101174. doi:10.1016/j.eclinm.2021.101174
5. Bloomfield LE, Ngeh S, Cadby G, Hutcheon K, Effler PV. SARS-CoV-2 Vaccine Effectiveness against Omicron Variant in Infection-Naive Population, Australia, 2022 - Volume 29, Number 6—June 2023 - Emerging Infectious Diseases Journal - CDC. *wwwnc.cdc.gov.* 2023;29. doi:10.3201/eid2906.230130
6. Yang J, Hong W, Lei H, et al. Low levels of neutralizing antibodies against XBB Omicron subvariants after BA.5 infection. *Signal Transduct Target Ther.* 2023;8(1):1-12. doi:10.1038/s41392-023-01495-4
7. Faustini S, Shields A, Banham G, et al. Cross reactivity of spike glycoprotein induced antibody against Delta and Omicron variants before and after third SARS-CoV-2 vaccine dose in healthy and immunocompromised individuals. *J Infect.* 2022;84(4):579-613. doi:10.1016/j.jinf.2022.01.002
8. Nguyenla XH, Bates TA, Trank-Greene M, Wahedi M, Tafesse FG, Curlin M. Evaluating Humoral Immunity Elicited by XBB.1.5 Monovalent COVID-19 Vaccine - Volume 30, Number 6—June 2024 - Emerging Infectious Diseases journal - CDC. doi:10.3201/eid3006.240051
9. Carr EJ, Wu MY, Gahir J, et al. Neutralising immunity to omicron sublineages BQ.1.1, XBB, and XBB.1.5 in healthy adults is boosted by bivalent BA.1-containing mRNA vaccination and previous Omicron infection. *Lancet Infect Dis.* 2023;23(7):781-784. doi:10.1016/S1473-3099(23)00289-X
10. Original COVID-19 priming regimen impacts the immunogenicity of bivalent BA.1 and BA.5 boosters | Nature Communications. Accessed August 30, 2024. <https://www.nature.com/articles/s41467-024-48414-x>
11. Vaksin Dashboard. Accessed March 14, 2024. <https://vaksin.kemkes.go.id/#/provinces>
12. 68.57 million Indonesians receive third COVID-19 vaccine dose - ANTARA News. Accessed March 14, 2024. <https://en.antaranews.com/news/268248/6857-million-indonesians-receive-third-covid-19-vaccine-dose>

13. Chen J, Wang R, Gilby NB, Wei GW. Omicron Variant (B.1.1.529): Infectivity, Vaccine Breakthrough, and Antibody Resistance. *J Chem Inf Model*. 2022;62(2):412-422. doi:10.1021/acs.jcim.1c01451
14. Hu B, Guo H, Zhou P, Shi ZL. Characteristics of SARS-CoV-2 and COVID-19. *Nat Rev Microbiol*. 2021;19(3):141-154. doi:10.1038/s41579-020-00459-7
15. Sun L, Shen L, Fan J, et al. Clinical features of patients with coronavirus disease 2019 from a designated hospital in Beijing, China. *J Med Virol*. 2020;92(10):2055-2066. doi:10.1002/jmv.25966
16. Brian DA, Baric RS. Coronavirus genome structure and replication. *Curr Top Microbiol Immunol*. 2005;287:1-30. doi:10.1007/3-540-26765-4_1
17. Plans-Rubió P. Percentages of Vaccination Coverage Required to Establish Herd Immunity against SARS-CoV-2. *Vaccines*. 2022;10(5):736. doi:10.3390/vaccines10050736
18. Naqvi AAT, Fatima K, Mohammad T, et al. Insights into SARS-CoV-2 genome, structure, evolution, pathogenesis and therapies: Structural genomics approach. *Biochim Biophys Acta Mol Basis Dis*. 2020;1866(10):165878. doi:10.1016/J.BBADIS.2020.165878
19. Zhang YZ, Holmes EC. A Genomic Perspective on the Origin and Emergence of SARS-CoV-2. *Cell*. 2020;181(2):223-227. doi:10.1016/j.cell.2020.03.035
20. Arya R, Kumari S, Pandey B, et al. Structural insights into SARS-CoV-2 proteins. *J Mol Biol*. 2021;433(2):166725. doi:10.1016/j.jmb.2020.11.024
21. Bai C, Zhong Q, Gao GF. Overview of SARS-CoV-2 genome-encoded proteins. *Sci China Life Sci*. 2022;65(2):280-294. doi:10.1007/s11427-021-1964-4
22. Rajpal VR, Sharma S, Sehgal D, et al. A comprehensive account of SARS-CoV-2 genome structure, incurred mutations, lineages and COVID-19 vaccination program. *Future Virol*. 2022;17(9):687-706. doi:10.2217/fvl-2021-0277
23. Yan W, Zheng Y, Zeng X, He B, Cheng W. Structural biology of SARS-CoV-2: open the door for novel therapies. *Signal Transduct Target Ther*. 2022;7(1). doi:10.1038/s41392-022-00884-5
24. Almehdi AM, Khoder G, Alchakee AS, Alsayyid AT, Sarg NH, Soliman SSM. SARS-CoV-2 spike protein: pathogenesis, vaccines, and potential therapies. *Infection*. 2021;49(5):855-876. doi:10.1007/s15010-021-01677-8
25. Wang MY, Zhao R, Gao LJ, Gao XF, Wang DP, Cao JM. SARS-CoV-2: Structure, Biology, and Structure-Based Therapeutics Development. *Front Cell Infect Microbiol*. 2020;10:587269. doi:10.3389/fcimb.2020.587269
26. Grobbelaar LM, Venter C, Vlok M, et al. SARS-CoV-2 spike protein S1 induces fibrin(ogen) resistant to fibrinolysis: Implications for microclot formation in COVID-19. *Biosci Rep*. 2021;41(8):0-1. doi:10.1042/BSR20210611
27. Huang Y, Yang C, Xu X feng, Xu W, Liu S wen. Structural and functional properties of SARS-CoV-2 spike protein: potential antiviral drug development for COVID-19. *Acta Pharmacol Sin*. 2020;41(9):1141-1149. doi:10.1038/s41401-020-0485-4
28. Artik Y, Kurtuluş MS, Uyar Y, et al. In-vitro for Q-RT-PCR Clinical Evaluation of Ocardia Ledovir Spray Effectiveness on SARS-CoV-2 and Its Effective Variants.

- Explor Res Hypothesis Med.* 2022;000(000):000-000. doi:10.14218/erhm.2022.00101
29. Bostanghadiri N, Ziaeefer P, Mofrad MG, Yousefzadeh P, Hashemi A, Darban-Sarokhalil D. COVID-19: An Overview of SARS-CoV-2 Variants—The Current Vaccines and Drug Development. Muddassir Ali M, ed. *BioMed Res Int.* 2023;2023(1):1879554. doi:10.1155/2023/1879554
 30. Cocherie T, Zafilaza K, Leducq V, et al. Epidemiology and Characteristics of SARS-CoV-2 Variants of Concern: The Impacts of the Spike Mutations. *Microorganisms.* 2022;11(1):30. doi:10.3390/microorganisms11010030
 31. Farhud DD, Mojahed N. SARS-COV-2 Notable Mutations and Variants: A Review Article. *Iran J Public Health.* Published online July 17, 2022. doi:10.18502/ijph.v51i7.10083
 32. Bai H, Zhang X, Gong T, et al. A systematic mutation analysis of 13 major SARS-CoV-2 variants. *Virus Res.* 2024;345:199392. doi:10.1016/j.virusres.2024.199392
 33. Flores-Vega VR, Monroy-Molina JV, Jiménez-Hernández LE, Torres AG, Santos-Preciado JI, Rosales-Reyes R. SARS-CoV-2: Evolution and Emergence of New Viral Variants. *Viruses.* 2022;14(4):653. doi:10.3390/v14040653
 34. Khadela A, Soni S, Megha K, Bhagat S, Chavda V. A Review on the Impact of the SARS-CoV-2 Omicron Subvariant on Elderly Patients with Diverse Co-Morbidities. *Biologics.* 2023;3(2):138-157. doi:10.3390/biologics3020008
 35. Tamura T, Irie T, Deguchi S, et al. Virological characteristics of the SARS-CoV-2 Omicron XBB.1.5 variant. *Nat Commun.* 2024;15(1):1176. doi:10.1038/s41467-024-45274-3
 36. Ling R, Dai Y, Huang B, et al. In silico design of antiviral peptides targeting the spike protein of SARS-CoV-2. *Peptides.* 2020;130(May):170328. doi:10.1016/j.peptides.2020.170328
 37. Shah VK, Firmal P, Alam A, Ganguly D, Chattopadhyay S. Overview of Immune Response During SARS-CoV-2 Infection: Lessons From the Past. *Front Immunol.* 2020;11(August):1-17. doi:10.3389/fimmu.2020.01949
 38. Chen Y, Zhao X, Zhou H, Zhu H, Jiang S, Wang P. Broadly neutralizing antibodies to SARS-CoV-2 and other human coronaviruses. *Nat Rev Immunol.* 2023;23(3):189-199. doi:10.1038/s41577-022-00784-3
 39. Morales-Núñez JJ, Muñoz-Valle JF, Torres-Hernández PC, Hernández-Bello J. Overview of neutralizing antibodies and their potential in COVID-19. *Vaccines.* 2021;9(12):1-22. doi:10.3390/vaccines9121376
 40. Garcia-Beltran WF, Lam EC, Astudillo MG, et al. COVID-19-neutralizing antibodies predict disease severity and survival. *Cell.* 2021;184(2):476-488.e11. doi:10.1016/j.cell.2020.12.015
 41. Burton DR. Antiviral neutralizing antibodies: from in vitro to in vivo activity. *Nat Rev Immunol.* 2023;23(11):720-734. doi:10.1038/s41577-023-00858-w
 42. Althuwaiqeb SA, Bordoni B. *Histology, B Cell Lymphocyte.* StatPearls Publishing; 2021. Accessed March 31, 2024. <https://www.ncbi.nlm.nih.gov/books/NBK560905/>

43. Akkaya M, Kwak K, Pierce SK. B cell memory: building two walls of protection against pathogens. *Nat Rev Immunol*. 2020;20(4):229-238. doi:10.1038/s41577-019-0244-2
44. Abbas AK, Lichtman AH, Pillai S, Baker DL. *Cellular and Molecular Immunology*. Tenth edition. Elsevier; 2022.
45. Klingler J, Weiss S, Itri V, et al. Role of IgM and IgA Antibodies in the Neutralization of SARS-CoV-2. *MedRxiv Prepr Serv Health Sci*. Published online 2020. doi:10.1101/2020.08.18.20177303
46. Wang Z, Muecksch F, Schaefer-Babajew D, et al. Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection. *Nature*. 2021;595(7867):426-431. doi:10.1038/s41586-021-03696-9
47. Lau EHY, Tsang OTY, Hui DSC, et al. Neutralizing antibody titres in SARS-CoV-2 infections. *Nat Commun*. 2021;12(1):1-7. doi:10.1038/s41467-020-20247-4
48. Trieu MC, Bansal A, Madsen A, et al. SARS-CoV-2-Specific Neutralizing Antibody Responses in Norwegian Health Care Workers after the First Wave of COVID-19 Pandemic: A Prospective Cohort Study. *J Infect Dis*. 2021;223(4):589-599. doi:10.1093/infdis/jiaa737
49. Sebai A, Mir G. COVID-19-neutralizing antibodies predict disease severity and survival | Elsevier Enhanced Reader. *CellPress*. 2020;(January). <https://reader.elsevier.com/reader/sd/pii/S0092867420316858?token=1A9023AC2130717EBCD5AB35A3001D28F6D8A0E5AFEC0C10D40DF7917A40C09E10A65BB68FCD90C63BE9750B2A7A7EC4&originRegion=eu-west-1&originCreation=20210516114136>
50. Khoury DS, Cromer D, Reynaldi A, et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. *Nat Med*. 2021;27(7):1205-1211. doi:10.1038/s41591-021-01377-8
51. Cromer D, Steain M, Reynaldi A, et al. Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysis. *Lancet Microbe*. 2022;3(1):e52-e61. doi:10.1016/S2666-5247(21)00267-6
52. Goto A, Miyakawa K, Nakayama I, et al. Prediction models for neutralization activity against emerging SARS-CoV-2 variants: A cross-sectional study. *Front Microbiol*. 2023;14(April):1-10. doi:10.3389/fmicb.2023.1126527
53. Sharma D, Rawat P, Greiff V, Janakiraman V, Gromiha MM. Predicting the immune escape of SARS-CoV-2 neutralizing antibodies upon mutation. *Biochim Biophys Acta BBA - Mol Basis Dis*. 2024;1870(2):166959. doi:10.1016/j.bbadis.2023.166959
54. Ferraz MVF, Moreira EG, Coêlho DF, Wallau GL, Lins RD. Immune evasion of SARS-CoV-2 variants of concern is driven by low affinity to neutralizing antibodies. *Chem Commun*. 2021;57(49):6094-6097. doi:10.1039/D1CC01747K
55. Nurisyah S, Iyori M, Hasyim AA, et al. Comparison between Neutralization Capacity of Antibodies Elicited by COVID-19 Natural Infection and Vaccination in


- Indonesia: A Prospective Cohort. *Antibodies*. 2023;12(3). doi:10.3390/antib12030060
56. Dhamad AE, Abdal Rhida MA. COVID-19: molecular and serological detection methods. *PeerJ*. 2020;8:e10180. doi:10.7717/peerj.10180
 57. APPLICATIONS OF BIOLUMINESCENCE. Accessed August 30, 2024. <http://photobiology.info/Ohmiya.html>
 58. SARS-CoV-2. Nexelis, a Q² Solutions Company. Accessed August 30, 2024. <https://nexelis.com/our-expertise/infectious-diseases/vaccine/sars-cov-2/>
 59. Chemaitelly H, Nagelkerke N, Ayoub HH, et al. Duration of immune protection of SARS-CoV-2 natural infection against reinfection. *J Travel Med*. 2022;29(8). doi:10.1093/jtm/taac109
 60. Chemaitelly H, Tang P, Hasan MR, et al. Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar. *N Engl J Med*. Published online 2021. doi:10.1056/nejmoa2114114
 61. Tartof SY, Slezak JM, Puzniak L, et al. Effectiveness and durability of BNT162b2 vaccine against hospital and emergency department admissions due to SARS-CoV-2 omicron sub-lineages BA.1 and BA.2 in a large health system in the USA: a test-negative, case-control study. *Lancet Respir Med*. Published online 2022. doi:10.1016/s2213-2600(22)00354-x
 62. Bates TA, Leier HC, McBride SK, et al. An extended interval between vaccination and infection enhances hybrid immunity against SARS-CoV-2 variants. *JCI Insight*. 2023;8(5). doi:10.1172/jci.insight.165265
 63. Matsumoto N, Sasaki A, Kadowaki T, Toshiharu Mitsushashi, Takao S, Takashi Yorifuji. Longitudinal antibody dynamics after COVID-19 vaccine boosters based on prior infection status and booster doses. *Sci Rep*. 2024;14(1). doi:10.1038/s41598-024-55245-9
 64. Underwood AP, Sølund C, Fernandez-Antunez C, et al. Durability and breadth of neutralisation following multiple antigen exposures to SARS-CoV-2 infection and/or COVID-19 vaccination. *EBioMedicine*. 2023;89:104475-104475. doi:10.1016/j.ebiom.2023.104475
 65. Ilenia Varasi, Lai A, Fiaschi L, et al. Neutralizing antibodies response to novel SARS-CoV-2 omicron sublineages in long-term care facility residents after the fourth dose of monovalent BNT162b2 COVID-19 vaccination. *J Infect J* *Journal Infect*. 2023;87(3):270-272. doi:10.1016/j.jinf.2023.06.019
 66. Varona JF, Muñoz J, Balboa-Barreiro V, et al. Persistence and Waning of Natural SARS-CoV-2 Antibodies Over 18 Months: Long-Term Durability of IgG Humoral Response in Healthcare Workers. *J Gen Intern Med*. 2022;37(10):2614-2616. doi:10.1007/s11606-022-07652-9
 67. Korosec CS, Dick DW, Moyles IR, Watmough J. SARS-CoV-2 Booster Vaccine Dose Significantly Extends Humoral Immune Response half-life beyond the Primary Series. *Sci Rep*. 2024;14(1):8426. doi:10.1038/s41598-024-58811-3
 68. Srivastava K, Carreño JM, Gleason C, et al. SARS-CoV-2-infection- and vaccine-induced antibody responses are long lasting with an initial waning phase followed

- by a stabilization phase. *Immunity*. 2024;57(3):587-599.e4. doi:10.1016/j.immuni.2024.01.017
69. Curlin ME, Bates TA, Guzman G, et al. Omicron Neutralizing Antibody Response following Booster Vaccination Compared with Breakthrough Infection. *Med*. Published online 2022. doi:10.1016/j.medj.2022.09.001
 70. Nishiyama T, Miyamatsu Y, Park H, et al. Modeling COVID-19 vaccine booster-elicited antibody response and impact of infection history. *Vaccine*. 2023;41(52):7655-7662. doi:10.1016/j.vaccine.2023.11.040
 71. Anshari Saifuddin Hasibuan, Sukamto Koesnoe, Widhani A, et al. Incidence and Associated Factors of SARS-CoV-2 Infection Post-mRNA-1273 Booster Vaccination in Health-Care Workers. *Vaccines*. 2023;11(2):481-481. doi:10.3390/vaccines11020481
 72. Glück V, Grobecker S, Köstler J, et al. Immunity after COVID-19 and vaccination: follow-up study over 1 year among medical personnel. *Infection*. 2021;38(9):1-8. doi:10.1007/s15010-021-01703-9
 73. Harapan H, Ar Royan H, Tyas II, et al. Waning anti-SARS-CoV-2 receptor-binding domain total antibody in CoronaVac-vaccinated individuals in Indonesia. *F1000Research*. 2023;11:1-22. doi:10.12688/f1000research.109676.2
 74. Moore SC, Kronsteiner B, Longet S, et al. Evolution of long-term vaccine-induced and Hybrid Immunity in Healthcare Workers after Different COVID-19 Vaccine Regimens. *Med*. 2023;4(3):191-215.e9. doi:10.1016/j.medj.2023.02.004
 75. Kannikar Intawong, Suwat Chariyalertsak, Kittipan Chalom, et al. Heterologous Booster Vaccines Reduce Severity and Mortality in COVID-19 during BA.2 and BA.4/BA.5 Omicron Predominance in Thailand. *Wēi-Miǎn Ũ Gǎnrǎn Zǎzhi Journal Microbiol Immunol Infect*. 2023;56(6):1178-1186. doi:10.1016/j.jmii.2023.10.001
 76. O'Shea KM, Schuler CF, Chen J, et al. Wild-type SARS-CoV-2 Neutralizing Immunity Decreases across Variants and over Time but Correlates Well with Diagnostic Testing. *Front Immunol*. 2023;14. doi:10.3389/fimmu.2023.1055429
 77. Chi X, Yan R, Zhang J, et al. A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2. *Science*. 2020;369(6504):650-655. doi:10.1126/science.abc6952
 78. Favresse J, Gillot C, Cabo J, David C, Dogné JM, Douxfils J. Neutralizing antibody response to XBB.1.5, BA.2.86, FL.1.5.1, and JN.1 six months after the BNT162b2 bivalent booster. *Int J Infect Dis*. 2024;143:107028. doi:10.1016/j.ijid.2024.107028
 79. Hussain S, Naseer F, Kanani F, Javeria Aijaz. Evaluating long-term Antibody Responses to Booster Doses of COVID-19 Vaccines in the Pakistani Population. *Pak J Med Sci*. 2023;40(2(ICON)). doi:10.12669/pjms.40.2(icon).8951
 80. Terbsiri V, Putcharoen O, Suwanpimolkul G, et al. Long-term Immunogenicity in Previously Vaccinated Healthcare Workers with Inactivated Virus Vaccine after SARS-CoV-2 Infection or Booster Vaccination. *Vaccine X*. 2023;14:100334. doi:10.1016/j.jvacx.2023.100334
 81. Zheng Y, Pan J, Jin M, et al. Efficacy of the Neutralizing Antibodies after the Booster Dose on SARS-CoV-2 Omicron Variant and a two-year Longitudinal

- Antibody Study on Wild Type Convalescents. *Int Immunopharmacol.* 2023;119:110151-110151. doi:10.1016/j.intimp.2023.110151
82. Liu Y, Liu J, Zou J, et al. Cross-neutralization and cross-protection among SARS-CoV-2 viruses bearing different variant spikes. *Signal Transduct Target Ther.* 2022;7(1):2020-2023. doi:10.1038/s41392-022-01137-1
 83. Crawford KHD, Dingens AS, Eguia R, et al. Dynamics of Neutralizing Antibody Titers in the Months after Severe Acute Respiratory Syndrome Coronavirus 2 Infection. *J Infect Dis.* 2020;223(2):197-205. doi:10.1093/infdis/jiaa618
 84. Wajnberg A, Amanat F, Firpo A, et al. Robust Neutralizing Antibodies to SARS-CoV-2 Infection Persist for Months. *Science.* 2020;370(6521):1227-1230. doi:10.1126/science.abd7728
 85. Shim SM, Kim JW, Jung S, et al. Persistence of the neutralizing antibody response after SARS-CoV-2 infection. *Clin Microbiol Infect.* 2022;28(4):614.e1-614.e4. doi:10.1016/j.cmi.2021.12.012
 86. Wu Y, Wang F, Shen C, et al. A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2. *Science.* 2020;368(6496):1274-1278. doi:10.1126/science.abc2241
 87. da Silva ES, Kohnen M, Gilson G, et al. Pre-Omicron Vaccine Breakthrough Infection Induces Superior Cross-Neutralization against SARS-CoV-2 Omicron BA.1 Compared to Infection Alone. *Int J Mol Sci.* 2022;23(14):7675. doi:10.3390/ijms23147675
 88. Sheward DJ, Kim C, Ehling RA, et al. Neutralisation Sensitivity of the SARS-CoV-2 Omicron (B.1.1.529) variant: a cross-sectional Study. *Lancet Infect Dis.* 2022;22(6):813-820. doi:10.1016/s1473-3099(22)00129-3
 89. Stamatatos L, Czartoski J, Wan YH, et al. mRNA Vaccination Boosts cross-variant Neutralizing Antibodies Elicited by SARS-CoV-2 Infection. *Science.* Published online 2021. doi:10.1126/science.abg9175
 90. Yu X, Qi X, Cao Y, et al. Three doses of an inactivation-based COVID-19 vaccine induces cross-neutralizing immunity against the SARS CoV-2 Omicron variant. *Emerg Microbes Infect.* 2022;11(1):749-752. doi:10.1080/22221751.2022.2044271
 91. Qu P, Faraone JN, Evans JP, et al. Enhanced evasion of neutralizing antibody response by Omicron XBB.1.5, CH.1.1, and CA.3.1 variants. *Cell Rep.* 2023;42(5):112443. doi:10.1016/j.celrep.2023.112443
 92. Dapporto F, Marchi S, Leonardi M, et al. Antibody Avidity and Neutralizing Response against SARS-CoV-2 Omicron Variant after Infection or Vaccination. *J Immunol Res.* 2022;2022:4813199. doi:10.1155/2022/4813199
 93. Memory B cells | Nature Reviews Immunology. Accessed September 25, 2024. <https://www.nature.com/articles/s41577-023-00897-3>
 94. Prather AA, Dutcher EG, Robinson J, et al. Predictors of long-term neutralizing antibody titers following COVID-19 vaccination by three vaccine types: the BOOST study. *Sci Rep.* 2023;13(1):6505. doi:10.1038/s41598-023-33320-x

Lampiran


Foto Kegiatan



Kegiatan Neutralizing Assay di Laboratory of Immunobiochemistry Musashino University, Tokyo, Jepang
(14 – 19 Januari 2024)



Foto bersama dengan Prof. Mitsuhiro Iyori selaku Pembimbing di Musashino University, Tokyo, Jepang
(19 Januari 2024)



Kegiatan Neutralizing Assay bersama Ammar Abdurrahman Hasyim di Laboratory of Applied Vaccinology, Kanazawa University, Kanazawa, Jepang (21 Januari – 25 Februari 2024)



Foto bersama dengan kolega dan pembimbing di Laboratory of Applied Vaccinology, Kanazawa University, Kanazawa, Jepang
kiri ke kanan: Ammar Abdurrahman, Prof. Akihiko Sakamoto, Kyouhei Yamagata, Penulis
(25 Februari 2024)

Persetujuan Etik



KEMENTERIAN PENDIDIKAN DAN KEBUDAYAAN
UNIVERSITAS HASANUDDIN FAKULTAS KEDOKTERAN
KOMITE ETIK PENELITIAN KESEHATAN
RSPTN UNIVERSITAS HASANUDDIN
RSUP Dr. WAHIDIN SUDIROHUSODO MAKASSAR
Sekretariat : Lantai 2 Gedung Laboratorium Terpadu
JL.PERINTIS KEMERDEKAAN KAMPUS TAMALANREA KM.10 MAKASSAR 90245.



Contact Person: dr. Agussalim Bukhari.,MMed,PhD, SpGK TELP. 081241850858, 0411 5780103, Fax : 0411-581431

REKOMENDASI PERSETUJUAN ETIK

Nomor : 182/ UN4.6.4.5.31 / PP36/ 2024

Tanggal: 20 Maret 2024

Dengan ini Menyatakan **Perpanjangan** Protokol dan Dokumen yang Berhubungan Dengan Protokol berikut ini telah mendapatkan Persetujuan Etik :

No Protokol	UH20110646	No Sponsor Protokol	
Peneliti Utama	dr. Yenni Yusuf, M.Infect.Dis, Ph.D	Sponsor	
Judul Penelitian	Studi imunologi pada penderita dan survivor COVID-19 sebagai dasar pengembangan dan implementasi vaksinasi		
No Versi Protokol	3	Tanggal Versi	18 Maret 2024
No Versi PSP	2	Tanggal Versi	28 Desember 2020
Tempat Penelitian	Laboratorium UNHAS Makassar dan Kanazawa University, Japan		
Dengan Nomor rekomendasi etik lama :	Nomor : 4/UN4.6.4.5.31/ PP36/ 2021		
Jenis Review	<input type="checkbox"/> Exempted <input type="checkbox"/> Expedited <input checked="" type="checkbox"/> Fullboard Tanggal 20 Maret 2024	Masa Berlaku 20 Maret 2024 sampai 20 Maret 2025	Frekuensi review lanjutan
Ketua Komisi Etik Penelitian Kesehatan FKUH	Nama Prof.dr. Muh Nasrum Massi, PhD.SpMK,Subsp.Bakt(K)	Tanda tangan	
Sekretaris Komisi Etik Penelitian Kesehatan FKUH	dr. Firdaus Hamid, PhD, SpMK(K)	Tanda tangan	

Kewajiban Peneliti Utama:

- Menyerahkan Amandemen Protokol untuk persetujuan sebelum di implementasikan
- Menyerahkan Laporan SAE ke Komisi Etik dalam 24 jam dan dilengkapi dalam 7 hari dan Laporan SUSAR dalam 72 jam setelah Peneliti Utama menerima laporan
- Menyerahkan Laporan Kemajuan (progress report) setiap 6 bulan untuk penelitian resiko tinggi dan setiap setahun untuk penelitian resiko rendah
- Menyerahkan laporan akhir setelah Penelitian berakhir
- Melaporkan penyimpangan dari protokol yang disetujui (protocol deviation / violation)
- Mematuhi semua peraturan yang ditentukan

Publikasi



**KEMENTERIAN PENDIDIKAN, KEBUDAYAAN,
RISET, DAN TEKNOLOGI
UNIVERSITAS HASANUDDIN
SEKOLAH PASCASARJANA**

Sekretariat lantai 3 Jl. Perintis Kemerdekaan KM. 10 Makassar, 90245

SURAT KETERANGAN JURNAL
Nomor: 8325/UN4.20/PJ.00.01/2024

Yang bertanda tangan di bawah ini menerangkan bahwa:

Nama : Karismananda

NIM : P062231027

Program Studi : Ilmu Biomedik

Judul Jurnal : Long-Term Immunity against SARS-CoV-2 Wild-Type and Omicron XBB.1.5 in Indonesian Residents after Vaccination and Infection

Naskah tersebut telah terakses online pada **Antibodies Journal (MDPI) (ISSN: 2073-4468)** diterbitkan pada **Volume 13 Issue 3 Tahun 2024, Doi: 10.3390/antib13030072** yang terindex **Scopus Q1** dan mempunyai **Impact factor (IF) 1,12**

Makassar, 05 September 2024

a.n Dekan,
Wakil Dekan Bidang Akademik,
Dan kemahasiswaan



Prof. Baharuddin Hamzah S.T., M. Arch., P.h.D.
NIP. 19690308 199512 1 001





antibodies



Article

Long-Term Immunity against SARS-CoV-2 Wild-Type and Omicron XBB.1.5 in Indonesian Residents after Vaccination and Infection

Karismananda, Ammar Abdurrahman Hasyim, Akihiko Sakamoto, Kyouhei Yamagata, Kartika Hardianti Zainal, Desi Dwirosalia Ningsih Suparman, Ika Yustisia, Marhaen Hardjo, Syahrijuita Kadir, Mitsuhiro Iyori et al.

Special Issue

Review Collection on Humoral Immunity

Edited by

Prof. Dr. Jagadeesh Bayry and Prof. Dr. Linqi Zhang



<https://doi.org/10.3390/antib13030072>

due to the reported mutations that can cause re-infection and subsequent consequences. The WHO report in December 2023 indicated a 53% increase in cases and a 51% increase in ICU admissions [2]. Furthermore, several studies have shown that post-COVID conditions, also known as long COVID-19, can cause severe and debilitating symptoms such as chronic fatigue, persistent respiratory issues, persistent muscle pain, sleep disorders, and cognitive impairments like brain fog [3]. Therefore, alertness against the potential for infection or re-infection with COVID-19 remains crucial in protecting public health. Given the uncertainty surrounding SARS-CoV-2, we must remain vigilant against the threat of this virus' mutations.

The Omicron variant of SARS-CoV-2 has demonstrated increased transmissibility and the ability to evade immunity derived from vaccines, although the first-generation vaccines still protect against severe illness and death [4]. The effectiveness of vaccines against Omicron infection is generally lower compared to previous variants, with protection decreasing rapidly over time [4–6]. A new COVID-19 vaccine containing targeting Omicron strain antigens was approved in 2023 to face this problem [7–9].

Vaccination in Indonesia started in January 2021, using two doses of Coronavac[®], the whole inactivated virus vaccine, at 4-week intervals. According to the Indonesian Ministry of Health, 86% of the population has received one dose, and 74% received the second dose. The first booster was introduced in August 2021 and reached 39% of residents in December 2022, while the second booster only covered 2% of the population in early 2023 [10]. The vaccination coverage leveled up since then, and there has been no significant increase in the number of individuals receiving vaccination since May 2022 [11]. Thus, the time gap between vaccination programs in Indonesia and the emergence of the Omicron strain can potentially reduce the level of immunity in the Indonesian population against the variant.

The continued evaluation of immune responses targeting circulating variants of SARS-CoV-2 is important to guide future vaccination strategies. Recently, at the end of 2023, the Indonesian population was struck by the XBB.1.5 variant of the Omicron strain, which caused the deaths of the elderly after a long pause in COVID-19-associated mortality [12]. This strain—emerging as the dominant strain in several countries—is more transmissible and has a superior capability to escape immunity [13,14]. Thus, several questions arose regarding the immune responses against this variant, such as the persistence of the humoral response induced by vaccinations and the effectivity of vaccine-induced antibodies in neutralizing the virus, particularly for the circulating Omicron XBB.1.5 strain. In addition, will we need to introduce a vaccine containing the Omicron antigen? This study was conducted to address those questions and to predict the vulnerability of the population to re-infection by emerging mutant strains of SARS-CoV-2.

2. Materials and Methods

2.1. Study Design and Study Subject

We conducted a cross-sectional study by recruiting individuals with different vaccination statuses by the number of booster doses using purposive sampling in Makassar, Indonesia's capital city of South Sulawesi Province, from November 2023 to January 2024 (Table 1). The inclusion criteria were those above 17 years old who had received two doses of the inactivated whole SARS-CoV-2 virus vaccine CoronaVac[®] from Sinovac at a 4-week interval as the primary vaccination. This study has been approved by the Ethics Committee of Hasanuddin University (Approval Number 182/UN4.6.4.5.31/PP36/2024).

Table 1. Grouping of study subjects based on their booster status.

Group	Vaccine Type		
	Primary Vaccine	1st Booster	2nd Booster
No booster	CoronaVac	-	-
1-time booster	CoronaVac	BNT162b2	-
2-times booster	CoronaVac	BNT162b2	mRNA1273

Blood was withdrawn after the subjects signed the informed consent form. We had also recorded the vaccination and infection history since January 2022. The collected blood was centrifuged for serum separation. All sera were kept at -80°C before being subjected to any experiments.

We recruited 113 subjects for the study from December 2023 to January 2024. The distribution of participants according to their vaccination status is summarized in Table 2. The proportion of participants who received two booster doses (DB group) was 41.59%, while those who received no booster dose (NB group) comprised 32.74% of the total subjects. The age varied across groups, with the highest median age observed in the participants with two booster doses (34.96 y.o, interval of 20–40 y.o). The infection status differed among the vaccination groups, with the highest percentage of confirmed infection history in the participants with two booster doses (29.78%). We recorded the confirmed breakthrough infection (BTI) in 2022 by PCR without any sequencing data.

Table 2. Distribution of study subjects by vaccination status.

Group *	n (%)	Sex		Age; Median (Interval; y.o)	Infection beyond 2021	
		Male; n (%)	Female; n (%)		Confirmed (%)	Untested # (%)
No booster (NB)	37 (32.74)	13 (35.13)	24 (64.86)	19.66 (17–23)	2/37 (5.4)	35/37 (94.59)
1-time booster (SB)	29 (25.66)	7 (24.13)	22 (75.86)	22.00 (17–53)	5/29 (17.24)	24/29 (82.75)
2-times booster (DB)	47 (41.59)	11 (23.4)	36 (76.59)	34.96 (20–40)	14/47 (29.78)	33/47 (70.21)

* NB: No booster; SB: Single booster; DB: Double booster. # subjects without any COVID-19 confirmatory test.

The timeline between the last vaccination and blood collection across three distinct groups categorized by their booster vaccination status is depicted in Figure 1. The average duration from the last vaccination dose to the subsequent blood sample collection was 25.11 weeks, 19.24 weeks, and 16.9 weeks for the NB, single booster (SB), and DB groups, respectively. The statistical analysis using the Kruskal–Wallis test confirmed significant differences in the mean duration among these groups ($p < 0.0001$). Further examination using Dunn’s multiple comparison tests highlighted significant disparities when comparing the SB and DB groups to the NB group ($p = 0.003$ and <0.0001 , respectively). Notably, while booster vaccinations contributed to variations in the timeline, the mean duration between the SB and DB groups was not significantly different ($p = 0.63$).

Among the participants, only 22 (19.46%) were confirmed to have contracted COVID-19 beyond 2021 (Table 3 and Figure 1). The mean duration from the confirmation of infection status to blood sampling was 21.72 (± 1.45) months. Specifically, 81% of the confirmed cases were health workers, comprising 50% community health center staff and 31.81% hospital staff. The remaining 18.18% worked in a health-service-unrelated environment. Interestingly, most confirmed infection groups (68.18%) had received a second booster dose. Other participants who had never undergone a confirmatory test were categorized as uninfected and were referred to as untested individuals.

Table 3. Characteristics of study subjects based on infection status.

Infection Status	n (%)	Sex		Age; Median (Interval; y.o)	Employment		Vaccination Status *			Duration from Last Infection in 2022; Mean \pm SD (Months)
		Male; n (%)	Female; n (%)		Health Worker n (%)	Others; n (%)	NB; n (%)	SB; n (%)	DB; n (%)	
Confirmed infection beyond 2021	22 (19.46)	1 (4.54)	21 (95.45)	33.23 (17–59)	18 (81.81)	4 (18.18)	1 (4.54)	6 (27.27)	15 (68.18)	21.72 (1.45)
Untested #	91 (80.53)	30 (32.96)	61 (67.03)	21.83 (17–59)	29 (31.86)	62 (68.13)	35 (38.46)	23 (25.27)	32 (35.16)	-

* NB: No booster; SB: Single booster; DB: Double booster. # subjects without any COVID-19 confirmatory test.




Figure 1. Schematic depiction of the vaccination timeline and breakthrough infections (BTI) for three groups based on booster status. The mean duration from the last vaccination to blood collection is 25.11 weeks for the no booster (NB) group, 19.24 weeks for the 1× booster (SB) group, and 16.9 weeks for the 2× booster (DB) group ($p < 0.0001$).

2.2. Laboratory Analysis

Before storage, the samples underwent heat inactivation to remove non-specific inhibition effects. This involved incubation at 56 °C in a circulating water bath for 30 min, followed by centrifugation at 15,000 rpm for 5 min at 4 °C. After heat inactivation, the samples were stored at −80 °C for subsequent analyses. All samples were subject to indirect ELISA for antibody titer assessment and pseudo-virus neutralizing assay for neutralization capacity (NC) evaluation.

Indirect ELISAs were performed using commercially available, HPLC-verified Wild-Type (WT) and XBB.1.5 RBD proteins as antigens (Sino Biological, Kawasaki City, Japan; #40591-V0811 for WT and #40592-V0811146 for XBB.1.5). The antibody titers are expressed as the optical density (OD) of the serum samples. As previously described, the same ELISA procedure was employed to measure the ODs, reflecting each sample's antibody (Ab)-binding capability to the respective antigens [15,16]. The 96-well microplates (Corning, Sakai, Japan, #3590) were coated with 0.2 µg/mL of either SARS-CoV-2 WT or the XBB.1.5 antigen and incubated overnight at 4 °C. Before incubation with the sera samples, the plates were blocked with 1% bovine serum albumin (BSA) in PBS (pH 7.4) for 1 h and then washed with PBS-T. The sera were diluted 1:100 in PBS containing 1% BSA. After incubation with sera for an hour, the plates were washed and then incubated with horseradish peroxidase (HRP)-conjugated monoclonal antibodies recognizing an Fc domain of human IgG for another hour. After incubation, the plates were rewashed, 100 µL/well of the substrate was added to each well, and the plates were incubated for 30 min at room temperature for color development. The absorbance was measured at 414 nm using a microplate reader, with results expressed as the Ab titers.

In the neutralization assay, the study emphasized assessing the overall trends in serological status rather than determining the exact neutralizing antibody (NAb) titers of individual samples. A brief assay can effectively correlate Ab OD with viral neutralization [15]. We utilized a VSV-based pseudo-virus expressing the Wuhan-Hu spike protein from earlier research [15,16]. Additionally, we engineered a pseudo-virus for this study that expresses the Omicron XBB.1.5 spike protein on its surface. To facilitate detection, we incorporated the luciferase gene into the viral genome. In the 96-well plate, 2 μL of serum was diluted in 48 μL of medium, followed by the addition of 50 μL of medium containing the pseudo-virus (3.2×10^4 TCID₅₀/well). Three wells without serum served as the controls. After incubation at 37 °C for 1 h, 100 μL of medium with 293T/hACE2+hTMPRSS2 cells (2×10^4 cells/well) was added. Following a 24-h incubation period, the ONE-Glo EX™ Luciferase Assay System (Promega, Madison, WI, USA) was used to determine the percentage of viral internalization by comparing the luminescence of the serum-treated wells to that of the control wells. The serum's NC was expressed as 100% minus the viral internalization percentage, reflecting the serum's ability to neutralize the virus.

2.3. Data Analysis

Statistical analysis was performed using GraphPad Prism version 10.0 for Mac OS. Kruskal–Wallis test with a post hoc Dunn's multiple comparison test was used for group analysis. A comparison between the two groups was made using the Mann–Whitney U test. Spearman correlation analysis and non-linear regression analysis were used to analyze the correlations between the Ab titers and the percentage of internalization. A *p*-value of <0.05 was considered statistically significant.

3. Results

3.1. Evaluation of the Persistence of Antibodies against Wild-Type SARS-CoV-2 and XBB.1.5

We first measured serum Ab titers against the RBD of the original WT and Omicron XBB.1.5 using ELISA to investigate the effect of booster doses and infection on long-term humoral immunity against COVID-19 (Figure 2). As expected, individuals with booster doses demonstrated higher Ab titers against the WT in a stepwise pattern (Figure 2A). The DB group showed the highest Ab titers, whereas the NB group showed the lowest titers (NB vs. SB vs. DB = 0.48 ± 0.03 vs. 0.54 ± 0.05 vs. 0.73 ± 0.03 , respectively). Interestingly, the anti-XBB.1.5 titer was higher than anti-WT titer in all subjects, yet the difference was not significant between the booster groups (Figure 2B). The mean anti-XBB.1.5 titer among the NB, SB, and DB groups was 1.43 ± 0.05 , 1.51 ± 0.06 , and 1.52 ± 0.06 , respectively. The vaccines failed to yield a significant increase in Ab titers against both strains in individuals with BTI (Figure 2C,D). Individuals with BTI exhibited an average anti-WT titer of 0.67 ± 0.05 , while those without BTI showed a titer of 0.59 ± 0.02 . On the other hand, the anti-XBB.1.5 RBD titer in individuals with a confirmed BTI was 1.50 ± 0.05 , and that in the untested individuals was 1.49 ± 0.04 . Further analysis showed that the Ab titers against WT and XBB.1.5 among individuals with pre-infection were not significantly different from those without pre-infection (Figure 2E,F).

The serum Ab titers against XBB.1.5 are higher (1.507 ± 0.03) than those against WT in all subjects (0.606 ± 0.02) ($p < 0.0001$) (Supplementary Figure S1A). The subgroup analysis based on the number of vaccines received revealed consistently higher XBB.1.5 Ab titers relative to WT across all subgroups (Supplementary Figure S1B; NB = 1.438 ± 0.05 vs. 0.48 ± 0.03 ; SB = 1.513 ± 0.06 vs. 0.549 ± 0.05 ; DB = 1.520 ± 0.06 vs. 0.737 ± 0.03), with $p < 0.0001$ observed in each subgroup. Similarly, based on infection status, the level of anti-WT and anti-XBB.1.5 Ab titers is significantly different (Supplementary Figure S1C). Anti-XBB.1.5 Ab titers surpassed WT Ab titers in the pre-infected individuals (1.5 ± 0.05 vs. 0.67 ± 0.05 , $p < 0.0001$) and in the untested group (1.49 ± 0.04 vs. 0.59 ± 0.02 , $p < 0.0001$).




Figure 2. Anti-RBD IgG titer of SARS-CoV-2 Wild-Type (WT) and Omicron XBB.1.5. While the booster doses affect the persistence of antibody (Ab) titers against SARS-CoV-2 WT (A), they do not affect the persistence of anti-XBB.1.5 Ab titer (B). Breakthrough infections (BTI) resulted in higher titer against WT SARS-CoV-2 (C) but no significant differences in anti-XBB.1.5 titer compared to non-infected participants (D). The Ab titers based on infection status and vaccine are shown in (E) and (F). The Ab titers of individuals with BTI beyond 2021 against WT (E) and XBB.1.5 (F) are not significantly different from vaccinated individuals without BTI. The antibody titers were measured using indirect ELISA and are expressed as ELISA's optical density (OD) measurements at 414 nm. Individual values are shown, and horizontal lines represent median and quartile of Ab titers. Statistical analyses were conducted using the Mann–Whitney test: **** $p < 0.0001$, ** $p < 0.01$.

3.2. Natural Infection Results in a Better Neutralization Capacity (NC)

Next, we investigated the serum Ab NC against WT and XBB.1.5 VSV pseudo-virus. As expected, the NC against Omicron XBB.1.5 was lower than that against the WT. While the number of booster doses did not significantly impact NC against WT (Figure 3A), individuals with two booster doses exhibited notably higher NC against XBB.1.5 pseudo-virus compared with those receiving one dose of booster or none (Figure 3B). Across the three booster groups, NC against WT remained comparable, with nearly 100% neutralization observed ($96.22 \pm 1.67\%$ for NB, $96.88 \pm 1.64\%$ for SB, and $97.93 \pm 0.55\%$ for DB).




Figure 3. A comparison of long-term neutralization capacity (NC). (A) Almost-complete NC against WT in all subjects. (B) Comparison of NC against XBB.1.5, with double booster (DB) groups having the highest NC compared to no booster (NB) and single booster (SB) groups. (C) Individuals with breakthrough infection (BTI) exhibit comparable NC against WT compared to the untested group. (D) Individuals with BTI demonstrate higher NC against XBB.1.5 than untested groups. (E,F) The effect of booster doses on WT NC and XBB.1.5 NC among individuals with confirmed BTI and those without BTI. Serum NC was measured using ONE-Glo EX™ Luciferase Assay System. Individual values are shown with bars that represent the means and horizontal lines that represent SEM. Statistical analyses were performed using the Mann-Whitney U test, * $p < 0.05$.

An increased NC against XBB.1.5, along with the increased number of booster doses, was observed, although the increment was not statistically significant. Specifically, the NC against XBB.1.5 among the NB, SB, and DB groups were $80.71 \pm 3.9\%$, $74.29 \pm 6.7\%$, and $67.2 \pm 6.3\%$, respectively. Given that NC for WT revealed nearly 100% neutralization for the majority of the sample, the NC was parallel between those with and those without BTI (Figure 3C).

A significant difference in NC against XBB.1.5 was demonstrated by individuals with BTI compared with those without ($90.29 \pm 3.89\%$ vs. $71.75 \pm 3.63\%$, respectively; Figure 3D; $p < 0.05$). The individuals with more booster doses demonstrated higher NC, especially those without BTI; however, a different case was shown with the pre-infected individuals, in whom the second booster did not result in antibodies with better NC (Figure 3E,F). The prevalence of pre-infected individuals with more than 50% neutralization of XBB.1.5 reduced from 100% to 80% after the second booster dose. On the other hand, the prevalence of uninfected individuals with more than 50% neutralization was 71%, 76%, and 84% in the NB, SB, and DB groups, respectively.

Supplementary Figure S2 clearly shows a comparative analysis of NC based on the strains of SARS-CoV-2. Evidently, NC against XBB.1.5 is lower than NC against WT in all subjects.

3.3. Correlation between Serum Antibody Titers and Neutralization Capacity for Wild-Type and Omicron XBB.1.5 Variants

We analyzed the relationship and model fit between Ab titers and their corresponding NC, as illustrated in Figure 4. Additionally, we examined the correlation and predictive score of Ab NC for the other variant. The Ab titers against the WT variant demonstrated a moderate negative correlation with their corresponding WT pseudo-virus internalization, as depicted in Figure 4A ($r = -0.3155$, $p < 0.0001$). A stronger cross-neutralization correlation was observed for the Omicron XBB.1.5 variant ($r = -0.439$, $p < 0.0001$), as shown in Figure 3C. A regression analysis revealed a minimal predictive relationship between WT Ab titers and their NC for both WT and XBB.1.5 variants ($R^2 = 0.064$ and $R^2 = 0.125$, respectively).

The antibodies targeting the Omicron XBB.1.5 variant (Figure 4B) also exhibited a moderate correlation with NC against their corresponding XBB.1.5 variant ($r = 0.3499$, $p < 0.001$). However, cross-neutralization capacity (cross-NC) against the WT variant showed no significant correlation, likely due to the low level of viral internalization demonstrated by all sera (Figure 3D) ($r = -0.182$, $p = 0.053$). The correlation and cross-correlation analysis displayed a limited predictive value ($R^2 = 0.1$ and $R^2 = 0.069$, respectively).

A subgroup analysis assessed the in-depth correlation between serum Ab titers and NC based on vaccination status and BTI history (Figure 3A–E). In the booster subgroup analysis, significant correlations were observed between Omicron XBB.1.5 Ab titers and NC in the NB group (Figure 3A, $r = -0.357$, $p = 0.035$) and SB group (Figure 3B, $r = -0.553$, $p < 0.001$). A regression analysis revealed moderate relationships between Ab titers and NC in these groups ($R^2 = 0.152$ and $R^2 = 0.311$, respectively). However, no significant correlation was found in the DB group (Figure 3C, $r = -0.146$, $p = 0.32$), with a meager regression score ($R^2 = 0.003$).

Conversely, for the WT variant, low and non-significant correlations were observed in both the NB (Figure 3A, $r = -0.106$, $p = 0.53$) and SB groups (Figure 3B, $r = -0.217$, $p = 0.24$). However, a significant correlation was detected in the DB group (Figure 3C, $r = -0.404$, $p < 0.01$), accompanied by a higher regression score ($R^2 = 0.26$) compared to the Omicron XBB.1.5 variant.

Moreover, individuals with BTI beyond 2021 exhibited similar NC for both the WT and Omicron XBB.1.5 variants (Figure 3D), resulting in comparable correlations between the serum Ab titers and NC in this group ($r = -0.272$, $p = 0.25$ and $r = -0.168$, $p = 0.49$, respectively). However, a notably better regression score was observed against Omicron XBB.1.5 ($R^2 = 0.476$); moreover, the untested individuals displayed significantly moderate correlations between Ab titers and NC against Omicron XBB.1.5 (Figure 3E; $r = -0.387$,

$p < 0.0001$). A regression analysis was only feasible for Omicron XBB.1.5 ($R^2 = 0.129$), as the regression for WT was exceedingly low ($R^2 < 0.0001$), which might be due to uniformly high NC against WT.




Figure 4. Correlation between antibody (Ab) titer and either neutralization capacity (NC) or cross-neutralization. A similar weak relationship between serum Ab titers and their respective NC was observed for both Wild-Type (WT) (blue dots) (A) and Omicron XBB.1.5 (orange dots) (B). Cross-correlation analysis between WT Ab titers and Omicron XBB.1.5 internalization (C); and Omicron XBB.1.5 Ab titers and WT internalization (D). Serum Ab titers were measured using indirect ELISA and are expressed as optical density at 414 nm, while serum NC was measured with the ONE-Glo EX™ Luciferase Assay System. Red lines depict the non-linear regression model between variables.

4. Discussion

Antibody titers against COVID-19, elicited from vaccination or infections, have been reported to decline over time and have become a growing concern [17–19]. Several studies suggest that vaccinations, particularly in individuals with pre-existing immunity, can initially boost Ab levels, gradually decreasing and stabilizing at lower levels over an extended period [4,20–24]. Our previous study on short-term immunity against the SARS-CoV-2 WT variant revealed that antibodies persisted at a high level at three months post-infection, yet no difference level between pre-infected individuals with uninfected vaccinated individuals was found [15]. In the current study, we evaluated the long-term immunity, at least one year ahead of the last vaccination, based on the number of booster doses and infection history beyond December 2021. Our current study confirms that booster doses have a pronounced effect on extending long-term immunity against WT and Omicron XBB.1.5 variants, particularly in individuals without infection history, as previously reported [25,26]. This is evidenced by the persistence of Ab titers and NC observed until 25 months after the last vaccination. Multiple reports suggest that BTI post-vaccination can significantly boost Ab titers, as evidenced by cases involving the Omicron variant infection following booster doses [20,27,28]. Recent studies indicate that individuals who received boosters and experienced BTI exhibit nearly double the amount of Ab titers compared to those without BTI, a phenomenon observed five months after receiving the booster [29].

However, in our study, we observed similar Ab titers between the post-infected individuals and the uninfected individuals. The Ab titer of the post-infected individuals, spanning approximately 21 months of the mean duration of the last known infections, may have spiked and decreased to eventually plateau at the same level as those of naïve vaccinated individuals when the blood sample was collected. The leveling off of the Ab titer may also be attributed to asymptomatic infections [30].

Neutralizing antibodies (NAbs) are pivotal in preventing SARS-CoV-2 infection, making the NAb activity assessment indispensable for addressing COVID-19 in diagnostic, therapeutic, and preventive contexts [31,32]. As NAb levels may decline over time and could be circumvented by viral mutations, continual monitoring of NAb activity is vital for guiding future prevention strategies [23,33]. Our study's findings reveal that individuals who received booster vaccinations demonstrate enhanced long-term neutralization against the Omicron variant compared to those who did not, particularly those without BTI history. One plausible explanation for this trend is the efficacy of heterologous boosters, observed among our study participants, in bolstering neutralizing responses more effectively than homologous boosters. This approach to heterologous boosting may mitigate the off-target immunity induced by different vaccine types [22,34,35].

Antibodies against SARS-CoV-2 neutralize the virus in several mechanisms, including blocking the interaction of the RBD with ACE2 by binding to the RBD or binding with a co-receptor (TMPRSS2), thus blocking the subsequent steps [36]. Therefore, natural infection may induce more complex antibodies that may be not only capable of binding to the receptor, but also to the co-receptor. Vaccine-induced antibodies may not be as effective as naturally-induced neutralizing antibodies, as the latter may target the N-terminal domain of the spike protein [37]. Our data show that BTI increased NC against Omicron, which is particularly evident among those who received one booster dose, similar to previous reports [21,38]. Cohort studies investigating booster effects have reported a 4.1-fold increase in NAb response following the third dose, rising further to 7.1 times with booster doses in BTI cases compared to primary vaccine recipients [27]. BTI after booster administration is associated with sustained neutralizing antibodies, observed over 6 months to 2 years, and a decelerated rate of NAb waning [39–41]. However, in our observation, the individuals with BTI who received the second booster dose did not show a higher NC compared to those who received the first dose. Thus, we assume that two doses of inactivated virus vaccine boosted with one dose of mRNA vaccine is sufficient for a long-term NC among individuals with a history of infection.

Another interesting finding from our study is the near-complete neutralization against the WT strain of most samples, even of those obtained from individuals without a booster. Despite the expectation of a decrease in NC over time, several reports indicate the persistence of NC against WT, and even potential increases due to exposure to the mutant variants. It has been reported that NAb gained from a mutation may also help cross-neutralization to WT [42]. The correlation between Ab titers and their corresponding NC offers valuable insights into the immunity against COVID-19 and the potential severity of infections [4,43]. Cohort studies measuring Ab titers alongside neutralization activity have shown persistent correlations, with Ab titers maintaining a solid correlation with their neutralization response for at least five months until nine months post-infection [44,45]. However, the applicability of this correlation may be limited over time, as Ab titers eventually reach detectable plateaus while maintaining stable neutralization activity, as elucidated above. Despite a notable correlation between Ab titers and NC in our findings, with correlations hovering around 0.3 for both metrics, it is crucial to interpret these results cautiously in the context of long-term evaluations. Therefore, interpreting Ab titers and their associated neutralization activity necessitates careful consideration in long-term immunity assessments against COVID-19. In addition, a study reported that antibodies produced by B-cell clones against RBD do not always compete with ACE2 for RBD binding [46].

It has been suggested that neither infection nor vaccination alone could induce potent cross-neutralization against Omicron [47–49]. In the current study, all subjects received

vaccination; therefore, we could not evaluate the impact of infection alone. A study reported that triple vaccination with an inactivated virus, even without BTI, demonstrated robust short-term cross-neutralization activity against both the Delta and Omicron variants [50]. In our study, the untested individuals with no confirmed BTI showed a lower neutralization activity than those with confirmed BTI. However, the NC against XBB.1.5 was still more than 70% in the naïve non-booster group, despite its waning due to longer duration than the other booster groups. This result is contradictory with a previous study showing almost complete XBB.1.5 evasion in three-dose-vaccinated sera after ten weeks [51] and another study showing that a two-dose vaccine produced antibodies with low avidity against the Omicron variant, but an additional dose increased the avidity [52].

This study has several limitations that warrant consideration. Firstly, its cross-sectional design, while providing rapid insights, may only partially capture the dynamics of long-term immunity. Thus, we could not evaluate the dynamic of the NC, the peak, or how long it was maintained at the same level. A prospective study would offer a more accurate assessment, not only for the dynamic of the immune response, but also in investigating infection history, which can sometimes go unnoticed during cross-sectional analyses. Thus, we prefer using the term “untested” for individuals without any confirmed infection. Moreover, we did not have data showing which SARS-CoV-2 strain circulated in Makassar, due to limited sequencing. Another limitation of this study was that the sample size was quite small. There was only one subject who had a confirmed infection in the no-booster group. Thus, we did not have sufficient data for a comparison between uninfected individuals and infected individuals in this group. Finally, we did not consider the variability of sex, age, body mass index, and smoking status of the study subjects, which were reported to correlate with the Ab-neutralizing activities [53]. Despite the limitations, this study has provided important information to guide future policies on COVID-19 vaccination in Indonesia. A two-dose whole-inactivated vaccine induced long-term immunity and sufficient cross-neutralization against mutant variants of SARS-CoV-2 for at least two years after vaccination, enhanced by booster doses in uninfected individuals.

5. Conclusions

The COVID-19 vaccine induced long-term immunity and cross-neutralization against the mutant variant of SARS-CoV-2 for at least 2 years post-administration in Indonesian residents. Individuals without booster doses maintain sufficient neutralizing capacity against the XBB.1.5. Booster doses enhanced the neutralization capacity, especially among naïve vaccinated individuals.

Supplementary Materials: The following supporting information can be downloaded at: <https://www.mdpi.com/article/10.3390/antib13030072/s1>, Figure S1: Significantly higher Omicron XBB.1.5 antibody titers compared to Wild-Type (WT) antibody titers (A). Subgroup comparisons also show consistently higher Omicron XBB.1.5 versus WT antibody titers among people who have not received a booster (no booster), received a single booster (1× booster), and received two boosters (2× booster) for both WT and XBB.1.5, as shown in (B). Anti-RBD XBB.1.5 titer is significantly higher than anti-RBD WT in both pre-infected individuals and untested individuals (C). The antibody titers were measured using indirect ELISA and are expressed as ELISA's optical density (OD) measurements at 414 nm. Individual values are shown, and horizontal lines represent median and quartile of Ab titers. Statistical analysis was performed using the mann-Whitney test (A) and the Kruskal-Wallis test (B & C). **** $p < 0.0001$, ** $p < 0.01$, * $p < 0.05$; Figure S2: Significantly higher serum neutralization capacity (NC) of Wild-Type (WT) compared to Omicron XBB.1.5 (A). Similarly, consistent results are also shown in the booster analysis subgroup among people who have not received a booster (no booster), received a single booster (1× booster), and received two boosters (2× booster), for both WT and XBB.1.5 (B). The NC against WT is higher than that against XBB.1.5. in both pre-infected and untested individuals (C). Serum NC was measured using ONE-Glo EX™ Luciferase Assay System. Individual values are shown with bars that represent the means and horizontal lines that represent SEM. Statistical analyses were performed using the Mann-Whitney U test and the Kruskal-Wallis test. **** $p < 0.0001$, ** $p < 0.01$, * $p < 0.05$; Figure S3: Subgroup Analysis of Correlation

Between Serum Antibody Titers and Neutralization Capacity (NC) for Respective Variants. Subgroup analysis by the number of booster doses (A–C) demonstrates a consistent relationship among non-booster recipients (A), single-booster recipients (B), and double-booster recipients (C). Similarly, subgroup analysis by infection status reveals comparable results for individuals with breakthrough infections (D) and untested individuals (E). The antibody titers were measured using indirect ELISA and are expressed as ELISA's optical density (OD) measurements at 414 nm, while the NC was measured using ONE-Glo EX™ Luciferase Assay System and expressed as the % internalization of the pseudovirus. Red lines and green lines depict the non-linear regression model between variables.

Author Contributions: Conceptualization, Y.Y.; methodology, A.S., K.Y., M.I. and S.Y.; validation, K., A.A.H., A.S., M.I. and Y.Y.; formal analysis, K., A.A.H. and Y.Y.; investigation, K., A.A.H., K.H.Z. and D.D.N.S.; resources, M.I., S.Y. and Y.Y.; data curation, K., A.A.H., A.S. and M.I.; writing—original draft preparation, K. and Y.Y.; writing—review and editing, A.A.H., A.S., I.Y., M.H., S.K., M.I. and Y.Y.; visualization, K.; supervision, A.S., I.Y., M.I., S.Y. and Y.Y.; project administration, K. and A.A.H.; funding acquisition, A.S., M.I., S.Y. and Y.Y. All authors have read and agreed to the published version of the manuscript.

Funding: This work was partly funded by the International Collaboration Research (I-CORE) Program, Equity World-Class University Indonesia Endowment Fund for Education Agency (WCU LPDP)-Institute of Research and Community Services (LPPM), Hasanuddin University to Y.Y. (No.04966/UN4.22/PT.01.03/2023); Indonesian Directorate General of Higher Education (DGHE) Japan Society for the Promotion of Science (JSPS) joint research projects to Y.Y. (No.003/E4.4/KU/2023) and M.I. (JPJSPB-120218101); and a Grant-in-Aid for Scientific Research© to M.I. (JSPS KAKENHI grant number 21K06559) and A.S. (JSPS KAKENHI grant number 21K06545). The APC was funded by Hasanuddin University.

Institutional Review Board Statement: This study was conducted in accordance with the Declaration of Helsinki and approved by the Ethics Committee of Hasanuddin University (Approval Number 182/UN4.6.4.5.31/PP36/2024).

Informed Consent Statement: Informed consent was obtained from all subjects involved in the study.

Data Availability Statement: The raw data supporting the conclusions of this article will be made available by the authors upon request.

Acknowledgments: We would like to express our sincere gratitude to all volunteers involved in this study. We are also grateful for the laboratory assistance of Sri Nur Rahmi Nur Rustam at the Center for Zoonotic and Emerging Diseases Laboratory, Faculty of Medicine, Hasanuddin University. We thank Syahrudin at Tadjuddin Chalid Hospital for the support during the sample collection.

Conflicts of Interest: The authors declare no conflicts of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.

References

1. World Health Organization. Statement on the Fifteenth Meeting of the IHR (2005) Emergency Committee on the COVID-19 Pandemic. Available online: [https://www.who.int/news/item/05-05-2023-statement-on-the-fifteenth-meeting-of-the-international-health-regulations-\(2005\)-emergency-committee-regarding-the-coronavirus-disease-\(covid-19\)-pandemic](https://www.who.int/news/item/05-05-2023-statement-on-the-fifteenth-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-coronavirus-disease-(covid-19)-pandemic) (accessed on 13 March 2024).
2. COVID-19 Epidemiological Update. 22 December 2023. Available online: <https://www.who.int/publications/m/item/covid-19-epidemiological-update--22-december-2023> (accessed on 13 March 2024).
3. Healey, Q.; Sheikh, A.; Daines, L.; Vasileiou, E. Symptoms and signs of long COVID: A rapid review and meta-analysis. *J. Glob. Health* **2022**, *12*, 05014. [CrossRef]
4. Lau, E.H.Y.; Hui, D.S.C.; Tsang, O.T.Y.; Chan, W.-H.; Kwan, M.Y.W.; Chiu, S.S.; Cheng, S.M.S.; Ko, R.L.W.; Li, J.K.C.; Chaotai, S.; et al. Long-term persistence of SARS-CoV-2 neutralizing antibody responses after infection and estimates of the duration of protection. *eClinicalMedicine* **2021**, *41*, 101174. [CrossRef] [PubMed]
5. Bloomfield, L.E.; Ngeih, S.; Cadby, G.; Hutcheon, K.; Effler, P.V. SARS-CoV-2 Vaccine Effectiveness against Omicron Variant in Infection-Naive Population, Australia, 2022. *Emerg. Infect. Dis. J.* **2023**, *29*, 6. [CrossRef]
6. Yang, J.; Hong, W.; Lei, H.; He, C.; Lei, W.; Zhou, Y.; Zhao, T.; Alu, A.; Ma, X.; Li, J.; et al. Low levels of neutralizing antibodies against XBB. Omicron subvariants after BA.5 infection. *Signal Transduct. Target. Ther.* **2023**, *8*, 252. [CrossRef]
7. Nguyenla, X.H.; Bates, T.A.; Trank-Greene, M.; Wahedi, M.; Tafesse, F.G.; Curlin, M. Evaluating Humoral Immunity Elicited by XBB.1.5 Monovalent COVID-19 Vaccine. *Emerg. Infect. Dis.* **2024**, *30*, 1282–1283. [CrossRef] [PubMed]

8. Carr, E.J.; Wu, M.Y.; Gahir, J.; Harvey, R.; Townsley, H.; Bailey, C.; Fowler, A.S.; Dowgier, G.; Hobbs, A.; Herman, L.; et al. Neutralising immunity to omicron sublineages BQ.1.1, XBB., and XBB.1.5 in healthy adults is boosted by bivalent BA.1-containing mRNA vaccination and previous Omicron infection. *Lancet Infect. Dis.* **2023**, *23*, 781–784. [CrossRef] [PubMed]
9. Zaack, L.M.; Tan, N.H.; Rietdijk, W.J.R.; Geers, D.; Sablerolles, R.S.G.; Bogers, S.; van Dijk, L.L.A.; Gommers, L.; van Leeuwen, L.P.M.; Rugebregt, S.; et al. Original COVID-19 priming regimen impacts the immunogenicity of bivalent BA.1 and BA.5 boosters. *Nat. Commun.* **2024**, *15*, 4224. [CrossRef]
10. Indonesia, K.K.R. Vaksinasi COVID-19 Nasional (National COVID-19 Vaccination). Available online: <https://vaksin.kemkes.go.id/#/vaccines> (accessed on 2 July 2024).
11. 57 Million Indonesians Receive Third COVID-19 Vaccine Dose. Available online: <https://en.antaranews.com/news/268248/685-7-million-indonesians-receive-third-covid-19-vaccine-dose> (accessed on 14 March 2024).
12. HAMASY, A.I.A. Dua Warga DKI Jakarta Meninggal Akibat COVID-19. Available online: <https://www.kompas.id/baca/metro/2023/12/11/dua-warga-dki-jakarta-meninggal-akibat-covid-19> (accessed on 12 April 2024).
13. Ao, D.; He, X.; Hong, W.; Wei, X. The rapid rise of SARS-CoV-2 Omicron subvariants with immune evasion properties: XBB.1.5 and BQ.1.1 subvariants. *MedComm* **2023**, *4*, e239. [CrossRef]
14. Chen, J.; Wang, R.; Gilby, N.B.; Wei, G.-W. Omicron Variant (B.1.1.529): Infectivity, Vaccine Breakthrough, and Antibody Resistance. *J. Chem. Inf. Model.* **2022**, *62*, 412–422. [CrossRef]
15. Nurisyah, S.; Iyori, M.; Hasyim, A.A.; Sakamoto, A.; Hashimoto, H.; Yamagata, K.; Yamauchi, S.; Amru, K.; Zainal, K.H.; Idris, I.; et al. Comparison between Neutralization Capacity of Antibodies Elicited by COVID-19 Natural Infection and Vaccination in Indonesia: A Prospective Cohort. *Antibodies* **2023**, *12*, 60. [CrossRef]
16. Sakamoto, A.; Osawa, H.; Hashimoto, H.; Mizuno, T.; Hasyim, A.A.; Abe, Y.-i.; Okahashi, Y.; Ogawa, R.; Iyori, M.; Shida, H.; et al. A replication-competent smallpox vaccine LC16m8A-based COVID-19 vaccine. *Emerg. Microbes Infect.* **2022**, *11*, 2359–2370. [CrossRef] [PubMed]
17. Chemaitelly, H.; Tang, P.; Hasan, M.R.; AlMukdad, S.; Yassine, H.M.; Benslimane, F.M.; Al Khatib, H.A.; Coyle, P.; Ayoub, H.H.; Al Kanaani, Z.; et al. Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar. *N. Engl. J. Med.* **2021**, *385*, e83. [CrossRef] [PubMed]
18. Chemaitelly, H.; Nagelkerke, N.; Ayoub, H.H.; Coyle, P.; Tang, P.; Yassine, H.M.; Al-Khatib, H.A.; Smatti, M.K.; Hasan, M.R.; Al-Kanaani, Z.; et al. Duration of immune protection of SARS-CoV-2 natural infection against reinfection. *J. Travel Med.* **2022**, *29*, taac109. [CrossRef]
19. Tartof, S.Y.; Slezak, J.M.; Puzniak, L.; Hong, V.; Frankland, T.B.; Xie, F.; Ackerson, B.K.; Valluri, S.R.; Jodar, L.; McLaughlin, J.M. Effectiveness and durability of BNT162b2 vaccine against hospital and emergency department admissions due to SARS-CoV-2 omicron sub-lineages BA.1 and BA.2 in a large health system in the USA: A test-negative, case-control study. *Lancet Respir. Med.* **2022**, *11*, 176–187. [CrossRef] [PubMed]
20. Bates, T.A.; Leier, H.C.; McBride, S.K.; Schoen, D.; Lyski, Z.L.; Xthona Lee, D.D.; Messer, W.B.; Curlin, M.E.; Tafesse, F.G. An extended interval between vaccination and infection enhances hybrid immunity against SARS-CoV-2 variants. *JCI Insight* **2023**, *8*, 165265. [CrossRef] [PubMed]
21. Matsumoto, N.; Sasaki, A.; Kadowaki, T.; Mitsushashi, T.; Takao, S.; Yorifuji, T. Longitudinal antibody dynamics after COVID-19 vaccine boosters based on prior infection status and booster doses. *Sci. Rep.* **2024**, *14*, 4564. [CrossRef]
22. Underwood, A.P.; Sølund, C.; Fernandez-Antunez, C.; Signe Lysemose, V.; Mikkelsen, L.S.; Ulrik, F.; Bollerup, S.; Anni Assing, W.; Uffe Vest, S.; Binderup, A.; et al. Durability and breadth of neutralisation following multiple antigen exposures to SARS-CoV-2 infection and/or COVID-19 vaccination. *eBioMedicine* **2023**, *89*, 104475. [CrossRef]
23. Ilenia, V.; Lai, A.; Fiaschi, L.; Bergna, A.; Gatti, A.; Caimi, B.; Biba, C.; Carla Della, V.; Balotta, C.; Riva, A.; et al. Neutralizing antibodies response to novel SARS-CoV-2 omicron sublineages in long-term care facility residents after the fourth dose of monovalent BNT162b2 COVID-19 vaccination. *J. Infect.* **2023**, *87*, 270–272. [CrossRef]
24. Varona, J.F.; Muñiz, J.; Balboa-Barreiro, V.; Peñalver, F.; Abarca, E.; Almiral, C.; Jose María, C. Persistence and Waning of Natural SARS-CoV-2 Antibodies Over 18 Months: Long-Term Durability of IgG Humoral Response in Healthcare Workers. *J. Gen. Intern. Med.* **2022**, *37*, 2614–2616. [CrossRef]
25. Korosec, C.S.; Dick, D.W.; Moyles, I.R.; Watmough, J. SARS-CoV-2 Booster Vaccine Dose Significantly Extends Humoral Immune Response half-life beyond the Primary Series. *Sci. Rep.* **2024**, *14*, 8426. [CrossRef]
26. Srivastava, K.; Carreño, J.M.; Gleason, C.; Monahan, B.; Singh, G.; Abbad, A.; Tcheou, J.; Raskin, A.; Kleiner, G.; van Bakel, H.; et al. SARS-CoV-2-infection- and vaccine-induced antibody responses are long lasting with an initial waning phase followed by a stabilization phase. *Immunity* **2024**, *57*, 587–599.e4. [CrossRef]
27. Curlin, M.E.; Bates, T.A.; Guzman, G.; Schoen, D.; McBride, S.K.; Carpenter, S.D.; Tafesse, F.G. Omicron Neutralizing Antibody Response following Booster Vaccination Compared with Breakthrough Infection. *Med. Xpress* **2022**, *3*, 827–837.e3. [CrossRef] [PubMed]
28. Nishiyama, T.; Miyamatsu, Y.; Park, H.; Nakamura, N.; Yokokawa Shibata, R.; Iwami, S.; Nagasaki, Y. Modeling COVID-19 vaccine booster-elicited antibody response and impact of infection history. *Vaccine* **2023**, *41*, 7655–7662. [CrossRef]
29. Anshari Saifuddin, H.; Sukambo, K.; Widhani, A.; Muhadi, M.; Hamzah, S.; Eka, G.; Evy, Y.; Pradana, S.; Sally Aman, N.; Samsuridjal, D.; et al. Incidence and Associated Factors of SARS-CoV-2 Infection Post-mRNA-1273 Booster Vaccination in Health-Care Workers. *Vaccines* **2023**, *11*, 481. [CrossRef] [PubMed]

30. Glück, V.; Grobecker, S.; Köstler, J.; Tydykov, L.; Bertok, M.; Weidlich, T.; Gottwald, C.; Salzberger, B.; Wagner, R.; Zeman, F.; et al. Immunity after COVID-19 and vaccination: Follow-up study over 1 year among medical personnel. *Infection* **2021**, *38*, 439–446. [[CrossRef](#)] [[PubMed](#)]
31. Abebe, E.C.; Dejenie, T.A. Protective Roles and Protective Mechanisms of Neutralizing Antibodies against SARS-CoV-2 Infection and Their Potential Clinical Implications. *Front. Immunol.* **2023**, *14*, 1055457. [[CrossRef](#)] [[PubMed](#)]
32. Burton, D.R. Antiviral Neutralizing antibodies: From in Vitro to in Vivo Activity. *Nat. Rev. Immunol.* **2023**, *23*, 720–734. [[CrossRef](#)]
33. Harapan, H.; Hibban Ar, R.; Islam Ing, T.; Auda, N.; Irham Faraby, A.; Anwar, S.; Husnah, M.; Ichsan, I.; Agung, P.; Mudatsir, M.; et al. Waning anti-SARS-CoV-2 receptor-binding Domain Total Antibody in CoronaVac-vaccinated Individuals in Indonesia. *F1000Research* **2023**, *11*, 300. [[CrossRef](#)]
34. Moore, S.C.; Kronsteiner, B.; Longet, S.; Adele, S.; Deeks, A.S.; Liu, C.; Dejnirattisai, W.; Reyes, L.S.; Meardon, N.; Faustini, S.; et al. Evolution of long-term vaccine-induced and Hybrid Immunity in Healthcare Workers after Different COVID-19 Vaccine Regimens. *Med* **2023**, *4*, 191–215.e9. [[CrossRef](#)]
35. Kannikar, I.; Suwat, C.; Kittipan, C.; Thanachol, W.; Woravut, K.; Aksara, T.; Narain, C.; Kajohnsak, N.; Krit, K.; Worachet, T.; et al. Heterologous Booster Vaccines Reduce Severity and Mortality in COVID-19 during BA.2 and BA.4/BA.5 Omicron Predominance in Thailand. *Wēi-Miān Yǔ Gānyǎn Zāzhì/J. Microbiol. Immunol. Infect.* **2023**, *56*, 1178–1186. [[CrossRef](#)]
36. Morales-Núñez, J.J.; Muñoz-Valle, J.F.; Torres-Hernández, P.C.; Hernández-Bello, J. Overview of Neutralizing Antibodies and Their Potential in COVID-19. *Vaccines* **2021**, *9*, 1376. [[CrossRef](#)]
37. Chi, X.; Yan, R.; Zhang, J.; Zhang, G.; Zhang, Y.; Hao, M.; Zhang, Z.; Fan, P.; Dong, Y.; Yang, Y.; et al. A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2. *Science* **2020**, *369*, 650–655. [[CrossRef](#)]
38. Favresse, J.; Gillot, C.; Cabo, J.; David, C.; Dogné, J.-M.; Douxfils, J. Neutralizing antibody response to XBB.1.5, BA.2.86, FL.1.5.1, and JN.1 six months after the BNT162b2 bivalent booster. *Int. J. Infect. Dis.* **2024**, *143*, 107028. [[CrossRef](#)]
39. Hussain, S.; Naseer, F.; Kanani, F.; Javeria, A. Evaluating long-term Antibody Responses to Booster Doses of COVID-19 Vaccines in the Pakistani Population. *Pak. J. Med. Sci.* **2023**, *40*, S28. [[CrossRef](#)] [[PubMed](#)]
40. Terbsiri, V.; Pucharoen, O.; Suwanpimolkul, G.; Jantarabenjakul, W.; Wacharapluesadee, S.; Champa, N.; Thippamom, N.; Paitoonpong, L. Long-term Immunogenicity in Previously Vaccinated Healthcare Workers with Inactivated Virus Vaccine after SARS-CoV-2 Infection or Booster Vaccination. *Vaccine X* **2023**, *14*, 100334. [[CrossRef](#)] [[PubMed](#)]
41. Zheng, Y.; Pan, J.; Jin, M.; Wang, J.; Tung, T.-H.; Chen, S.; Bi, X.; Zhou, K.; Chen, M.; Wang, D.; et al. Efficacy of the Neutralizing Antibodies after the Booster Dose on SARS-CoV-2 Omicron Variant and a two-year Longitudinal Antibody Study on Wild Type Convalescents. *Int. Immunopharmacol.* **2023**, *119*, 110151. [[CrossRef](#)] [[PubMed](#)]
42. Liu, Y.; Liu, J.; Zou, J.; Kalveram, B.; Machado, R.R.G.; Ren, P.; Türel, S.; Smith, D.J.; Weaver, S.C.; Xie, X.; et al. Cross-neutralization and cross-protection among SARS-CoV-2 Viruses Bearing Different Variant Spikes. *Signal Transduct. Target. Ther.* **2022**, *7*, 285. [[CrossRef](#)] [[PubMed](#)]
43. Crawford, K.H.D.; Dingens, A.S.; Eguia, R.; Wolf, C.R.; Wilcox, N.; Logue, J.K.; Shuey, K.; Casto, A.M.; Fiala, B.; Wrenn, S.; et al. Dynamics of Neutralizing Antibody Titers in the Months after Severe Acute Respiratory Syndrome Coronavirus 2 Infection. *J. Infect. Dis.* **2020**, *223*, 197–205. [[CrossRef](#)]
44. Wajnberg, A.; Amanat, F.; Firpo, A.; Altman, D.R.; Bailey, M.J.; Mansour, M.; McMahon, M.; Meade, P.; Mendu, D.R.; Muellers, K.; et al. Robust Neutralizing Antibodies to SARS-CoV-2 Infection Persist for Months. *Science* **2020**, *370*, 1227–1230. [[CrossRef](#)]
45. Shim, S.-M.; Kim, J.-W.; Jung, S.; Jung, Y.; Woo, H.-M.; Yang, J.-S.; Kim, K.-C.; Lee, J.-Y. Persistence of the Neutralizing Antibody Response after SARS-CoV-2 Infection. *Clin. Microbiol. Infect.* **2021**, *28*, 614.e1–614.e4. [[CrossRef](#)]
46. Wu, Y.; Wang, F.; Shen, C.; Peng, W.; Li, D.; Zhao, C.; Li, Z.; Li, S.; Bi, Y.; Yang, Y.; et al. A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2. *Science* **2020**, *368*, 1274–1278. [[CrossRef](#)] [[PubMed](#)]
47. Sheward, D.J.; Kim, C.; Ehling, R.A.; Pankow, A.; Castro Dopico, X.; Dyrdak, R.; Martin, D.P.; Reddy, S.T.; Dillner, J.; Karlsson Hedestam, G.B.; et al. Neutralisation Sensitivity of the SARS-CoV-2 Omicron (B.1.1.529) variant: A cross-sectional Study. *Lancet Infect. Dis.* **2022**, *22*, 813–820. [[CrossRef](#)] [[PubMed](#)]
48. da Silva, E.S.; Kohnen, M.; Gilson, G.; Staub, T.; Arendt, V.; Hilger, C.; Servais, J.-Y.; Charpentier, E.; Domingues, O.; Snoeck, C.J.; et al. Pre-Omicron Vaccine Breakthrough Infection Induces Superior Cross-Neutralization against SARS-CoV-2 Omicron BA.1 Compared to Infection Alone. *Int. J. Mol. Sci.* **2022**, *23*, 7675. [[CrossRef](#)] [[PubMed](#)]
49. Stamatatos, L.; Czartoski, J.; Wan, Y.-H.; Homad, L.J.; Rubin, V.; Glantz, H.; Neradilek, M.; Seydoux, E.; Jennewein, M.F.; MacCamy, A.J.; et al. mRNA Vaccination Boosts cross-variant Neutralizing Antibodies Elicited by SARS-CoV-2 Infection. *Science* **2021**, *372*, 1413–1418. [[CrossRef](#)]
50. Yu, X.; Qi, X.; Cao, Y.; Li, P.; Lu, L.; Wang, P.; Feng, Y.; Yang, J.; Wei, H.; Guo, L.; et al. Three Doses of an inactivation-based COVID-19 Vaccine Induces cross-neutralizing Immunity against the SARS CoV-2 Omicron Variant. *Emerg. Microbes Infect.* **2022**, *11*, 749–752. [[CrossRef](#)]
51. Qu, P.; Faraone, J.N.; Evans, J.P.; Zheng, Y.-M.; Carlin, C.; Anghelina, M.; Stevens, P.; Fernandez, S.; Jones, D.; Panchal, A.R.; et al. Enhanced evasion of neutralizing antibody response by Omicron XBB.1.5, CH.1.1, and CA.3.1 variants. *Cell Rep.* **2023**, *42*, 112443. [[CrossRef](#)]

52. Dapporto, F.; Marchi, S.; Leonardi, M.; Piu, P.; Lovreglio, P.; Decaro, N.; Buonvino, N.; Stufano, A.; Lorusso, E.; Bombardieri, E.; et al. Antibody Avidity and Neutralizing Response against SARS-CoV-2 Omicron Variant after Infection or Vaccination. *J. Immunol. Res.* **2022**, *2022*, 4813199. [[CrossRef](#)]
53. Prather, A.A.; Dutcher, E.G.; Robinson, J.; Lin, J.; Blackburn, E.; Hecht, F.M.; Mason, A.E.; Fromer, E.; Merino, B.; Frazier, R.; et al. Predictors of long-term neutralizing antibody titers following COVID-19 vaccination by three vaccine types: The BOOST study. *Sci. Rep.* **2023**, *13*, 6505. [[CrossRef](#)]

Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Data

kode sampel	titer antibodi (OD)		Netralisasi terhadap virus						
	WT	XBB.1.5	WT NC (n1)	WT NC (n2)	WT NC (n3)	XBB.1.5 (n1)	XBB.1.5 (n2)	XBB.1.5 (n3)	
A1	0,504	1,424	100	100	94,8	73,64	80,92	90,62	
A2	0,467	0,999	99,48	99,99	99,98	37,66	16,93	70,08	
A3	0,624	1,337	99,89	99,99	100	72,81	88,03	92,37	
A4	0,329	1,608	97,9	99,99	99,99	75,86	89,54	95,27	
A5	0,82	1,909	93,97	99,97	100	100,03	99,94	100,04	
A6	0,56	1,558	99,93	99,91	98,77	0	13,01	38,15	
A7	0,205	0,854	35,26	9,66	76,46	100,02	99,45	99,8	
A8	0,416	1,395	99,49	93,06	67,51	-28,18	9,85	-41,13	
A9	0,397	1,726	99,99	100	99,03	73,64	80,92	90,62	
A10	0,182	0,862	99,47	99,97	99,92	37,66	16,93	70,08	
A11	0,323	1,327	99,95	99,98	84,83	72,81	88,03	92,37	
A12	0,286	1,342	99,42	99,77	99,96	75,86	89,54	95,27	
A13	0,397	1,162	99,99	100	92,15	100,03	99,94	100,04	
A14	0,424		99,98	99,95	79,74	0	13,01	38,15	
A15	0,165	0,793	91,32	99,9	99,94	-28,18	9,85	-41,13	
A16	0,64	1,515	100	100	100	96,63	85	96,55	
A17	0,399	1,178	99,77	95,44	85,74	74,76	88,81	63,17	
A18	0,632	1,947	98,76	99,97	99,92	47,62	48,61	69,88	
A19	0,411	1,385	99,98	99,99	99,99	99,86	100	100	
A20	0,516	1,954	100	100	97,37	86,85	96,13	95,81	
A21	0,441	1,209	100	99,97	99,99	0,67	-32,83	6,85	
A22	0,752	1,44	98,24	99,99	100	17,2	52,82	45,86	
A23	0,569	1,516	99,86	99,99	100	90,73	91,32	94,54	
A24	0,341	1,324	99,66	99,7	87,81	70,48	61,57	81,28	
A25	0,89	1,699	95,81	99,95	99,93	100	99,43	98,93	
A26	0,404	1,439	99,62	99,6	99,75	98,6	96,93	96,58	
A27	0,805	1,589	99,95	99,94	99,92	98,16	100	94,33	
A28	0,868	1,819	99,68	99,64	91,8	99,56	100	99,41	
A29	0,57	1,387	100,03	78,34	100,01	87	97,92	90,39	
A30	0,279	1,569	99,78	100,02	97,49	77,19	76,49	76,75	
A31	0,382	1,169	100,02	100	100,02	73,65	83,67	77,26	
A32	0,739	1,818	100,02	95,27	100,02	97,26	100	100	
A33	0,535	1,79	87,02	82,22	99,94	94,64	100,02	95,22	
A34	0,206	1,381	99,98	99,99	99,99	36,01	35,01	58,42	
A35	0,541	1,598	99,99	99,99	100	55,71	64,89	58,73	
A36	0,261	1,307	99,91	98,08	95,05	-12,04	-7,14	-21,67	

kode sampel	titer antibodi (OD)		Netralisasi terhadap virus					
	WT	XBB.1.5	WT NC (n1)	WT NC (n2)	WT NC (n3)	XBB.1.5 (n1)	XBB.1.5 (n2)	XBB.1.5 (n3)
B1	0,784	1,542	99,99	99,97	100,02	90,28	96,2	100,03
B2	0,575	1,818	100	94,26	87,35	94,64	100,02	95,22
B3	0,167	0,858	91,35	94,99	98,1	1,35	38,27	-9,44
B4	0,26	1,15	99,98	99,92	100,02	36,01	35,01	58,42
B5	0,523	1,213	100	100	97,09	60,31	100,02	99,51
B6	0,259	0,764	86,13	18,14	47,48	-13,95	4,25	-46,18
B7	0,989	1,869	81,76	97,46	100,03	100,01	97,44	96,14
B8	0,518	1,473	99,81	99,94	100,02	56,87	74,75	34,57
B9	-0,025	1,325	100	99,91	100	73,64	80,92	90,62
B10	0,201	0,796	99,92	99,93	99,98	72,81	88,03	92,37
B11	0,411	1,705	99,98	100	100	100,03	99,94	100,04
B12	1,013	2,02	99,95	100	99,99	0	13,01	38,15
B13	0,693	1,62	96,99	99,98	100	100,02	99,45	99,8
B14	0,454	1,461	88,32	96,23	99,96	-28,18	9,85	-41,13
B15	0,99	1,68	99,98	100	100	94,86	91,74	92,34
B16	0,696	1,435	99,97	99,95	100	81,17	54,63	80,01
B17	0,602	1,582	100	100	100	85,63	88,39	89,58
B18	0,372	1,98	98,89	99,99	92,68	99,13	94,38	98,81
B19	0,943	2,074	97,02	99,99	99,98	100	99,44	99,99
B20	0,598	1,966	99,96	100	100	88,25	68,09	90,36
B21	0,122	1,134	97,89	98,51	92,1	-29,75	12,78	41,38
B22	0,72	1,813	99,98	99,99	99,99	95,75	95,66	96,25
B23	0,281	1,581	99,99	98,85	99,89	91,54	97,23	97,65
B24	0,319	1,135	99,96	93,56	99,97	81,59	80,32	74,13
B25	0,425	1,371	99,94	99,95	99,95	96,48	95,03	92,83
B26	0,721	1,404	100,03	90,45	89,7	100	100	98,2
B27	1,342	1,892	96,97	100,02	100,02	100	100	100
B28	0,596	1,592	100,03	100,03	100,03	98,58	95,39	92,19
B29	0,537	1,777	100	98,29	100,03	100	99,99	97,52
B30	0,411	1,356	99,99	99,98	99,95	100,02	99,45	99,8

kode sampel	titer antibodi (OD)		Netralisasi terhadap virus					
	WT	XBB.1.5	WT NC (n1)	WT NC (n2)	WT NC (n3)	XBB.1.5 (n1)	XBB.1.5 (n2)	XBB.1.5 (n3)
C1	0,782	1,826	90,2	99,92	100,02	49,37	67,14	63,53
C2	0,778	2,162	99,88	99,98	100,02	100,04	100,01	93,26
C3	0,717	0,1	99,94	100	100,01	90,4	87,98	89,78
C4	0,449	1,875	99,99	83,79	100,02	43,4	33,02	42,86
C5	0,803	1,929	95,04	99,95	99,81	93,46	99,96	99,97
C6	0,842	1,59	99,96	99,99	100,01	99,63	91,14	100,02
C7	0,225	1,222	99,98	98,62	100,02	46,5	21,98	33,41
C8	0,95	1,365	100	100	100	60,51	49,54	48,32
C9	0,817	1,615	92,29	94,7	99,11	90,28	96,2	100,03
C10	1,082	1,788	99,94	99,98	99,97	94,64	100,02	95,22
C11	0,935	1,746	100	99,99	100	1,35	38,27	-9,44
C12	0,312	1,618	95,18	86,92	78,14	36,01	35,01	58,42
C13	0,419	1,596	99,97	93,32	99,36	60,31	100,02	99,51
C14	0,738	2,01	99,99	99,98	99,99	-13,95	4,25	-46,18
C15	0,706	1,715	88,03	99,97	99,99	100,01	97,44	96,14
C16	0,77	1,88	100	100	99,86	56,87	74,75	34,57
C17	0,883	1,775	100	99,76	100	85,25	95,63	94,91
C18	0,228	1,152	100	90,4	99,91	53,19	49,54	49,47
C19	0,608	1,365	99,99	99,97	99,87	100	100	100
C20	0,423	1,31	99,99	99,99	94,15	95,5	100,01	95,01
C21	1,07	1,929	99,99	100	99,99	99,16	99,85	94,89
C22	0,896	1,847	100	100	99,98	82,36	76,76	91,37
C23	0,325	1,31	99,98	100	100	86,58	98,93	96,58
C24	0,513	1,66	96,1	99,98	99,99	100	100,01	99,95
C25	0,466	1,673	100	99,94	99,99	91,98	95,97	96,36
C26	0,991	1,887	99,99	94,17	99,98	99,98	99,99	100,01
C27	0,81	1,841	100	99,98	99,99	90,89	92,16	88,73
C28	0,278	1,343	73,51	85,22	78,77	96,62	93,31	93,96
C29	0,244	0,66	100,02	84,52	99,79	64,14	53,52	31,45
C30	0,774	1,67	100	75,85	100,02	88,27	84,6	87,75
C31	0,928	1,523	100,03	88,43	100,02	99,76	100	100
C32	0,666	0,675	89,55	93,28	97,1	80,8	79,66	77,05
C33	1,338	1,833	100,02	100,02	100,02	100	99,99	100
C34	0,772	0,981	100,02	100,02	100,02	84,55	81,48	69,81
C35	0,833	1,852	100,02	95,62	100,03	97,48	99,75	100
C36	0,81	1,899	100,02	100,02	100,03	95,81	99,93	98,84
C37	0,83	1,374	86,72	99,87	99,98	100,05	94,02	86,49
C38	0,891	1,531	100,02	99,61	100,03	100,04	81,44	100,04
C39	1,343	1,664	99,99	100,03	100,03	100,05	99,98	100,01
C40	0,82	1,684	100,02	100,02	100,02	86,07	33,48	12,68
C41	0,767	1,529	100,02	100,03	100,03	100,05	94,02	86,49
C42	0,512	1,841	100,03	100,03	99,99	100,04	99,86	84,71
C43	0,881	1,93	100,02	100,02	100,03	100,04	81,44	100,04
C44	0,9	1,476	100,02	100,02	100,03	100,05	99,98	100,03
C45	1,201	1,688	100,02	99,61	100,01	100,05	99,98	100,01
C46	0,618	0,994	100,02	100,01	86,42	86,07	33,48	12,68
C47	0,605	1,404	100,02	100,02	99,99	100,04	99,86	84,71
C48	0,862	1,208	100,02	100,02	99,84	100,05	99,98	100,03